| Title |
Inhaled corticosteroids with combination inhaled long-acting beta2 -agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease
|
|---|---|
| Published in |
Cochrane database of systematic reviews, November 2016
|
| DOI | 10.1002/14651858.cd011600.pub2 |
| Pubmed ID | |
| Authors |
Daniel J Tan, Clinton J White, Julia AE Walters, E Haydn Walters |
| Abstract |
Management of chronic obstructive pulmonary disease (COPD) commonly involves long-acting bronchodilators including beta-agonists (LABA) and muscarinic antagonists (LAMA). In individuals with persistent symptoms or frequent exacerbations, inhaled corticosteroids (ICS) are also used. LABA and LAMA bronchodilators are now available in single combination inhalers. However, the benefits and risks of adding ICS to combination LABA/LAMA inhalers remains unclear. To assess the effect of adding an inhaled corticosteroid (ICS) to combination long-acting beta₂-agonist (LABA)/long-acting muscarinic antagonist (LAMA) inhalers for the treatment of stable COPD. We carried out searches using the Cochrane Airways Group Specialised Register of Trials (searched 20 September 2016), Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 12) in the Cochrane Library (searched 15 December 2015) and MEDLINE (searched 15 December 2015). We also searched ClinicalTrials.gov, World Health Organisation (WHO) trials portal and pharmaceutical company clinical trials' databases up to 7 Janurary 2016. We included parallel-group, randomised controlled trials (RCTs) of three weeks' duration or longer which compared treatment of stable COPD with ICS in addition to combination LABA/LAMA inhalers against combination LABA/LAMA inhalers alone. We used standard methodological procedures expected by Cochrane. We identified a total of 586 records in our search. Following removal of duplicates, 386 abstracts were assessed for inclusion. Six studies were identified as potentially relevant; however, all failed to meet the inclusion criteria on full-text assessment or after contacting the corresponding author to clarify study characteristics. There are currently no studies published assessing the effect of ICS in addition to combination LABA/LAMA inhalers for the treatment of stable COPD. As combination LABA/LAMA inhalers are now widely available, there is a need for well-designed RCTs to investigate whether ICS provides any added therapeutic benefit. |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 7 | 50% |
| United Kingdom | 1 | 7% |
| United States | 1 | 7% |
| Unknown | 5 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 93% |
| Practitioners (doctors, other healthcare professionals) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 98 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 98 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 16 | 16% |
| Researcher | 12 | 12% |
| Student > Bachelor | 10 | 10% |
| Student > Postgraduate | 7 | 7% |
| Other | 6 | 6% |
| Other | 17 | 17% |
| Unknown | 30 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 39% |
| Nursing and Health Professions | 9 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 7% |
| Psychology | 3 | 3% |
| Biochemistry, Genetics and Molecular Biology | 2 | 2% |
| Other | 6 | 6% |
| Unknown | 33 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2021.
All research outputs
#1,661,282
of 24,116,965 outputs
Outputs from Cochrane database of systematic reviews
#3,743
of 12,842 outputs
Outputs of similar age
#30,495
of 317,116 outputs
Outputs of similar age from Cochrane database of systematic reviews
#97
of 276 outputs
Altmetric has tracked 24,116,965 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.9. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,116 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 276 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.